SCHEMBL2336044

SCHEMBL2336044

O=C(O)Cc1cccc(Cl)c1C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.62
DUSP3 P51452 1/20 0.59
PTPN5 P54829 1/20 0.59
PTPN11 Q06124 1/20 0.59
CTDSP1 Q9GZU7 1/20 0.59
CXCL8 P10145 3/20 0.54
TTR P02766 2/20 0.54
PTGS2 P35354 2/20 0.54
AKR1B10 O60218 1/20 0.54
UGT1A9 O60656 1/20 0.54
TRPA1 O75762 1/20 0.54
ABCB11 O95342 1/20 0.54
MT-CO2 P00403 1/20 0.54
ALB P02768 1/20 0.54
UGT1A6 P19224 1/20 0.54
UGT1A1 P22309 1/20 0.54
PTGS1 P23219 1/20 0.54
CXCR1 P25024 1/20 0.54
ADRA1A P35348 1/20 0.54
AGTR2 P50052 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27853749 0.84 ALDH1A1 (0.50) AKR1B1FABP4ALDH1A1FEN1
SCHEMBL11691926 0.82 AKR1B1 (0.77) AKR1B1DUSP3PTPN5PTPN11CTDSP1
SCHEMBL3006057 0.82 ALDH1A1 (0.48) AKR1B1CXCL8TTRPTGS2AKR1B10
SCHEMBL4504893 0.82 ALDH1A1 (0.48) AKR1B1FABP4ALDH1A1FEN1
SCHEMBL8477197 0.82 ALDH1A1 (0.48) AKR1B1CXCL8TTRPTGS2AKR1B10
SCHEMBL2547244 0.82 AKR1B1 (0.63) AKR1B1CXCL8TTRPTGS2AKR1B10
SCHEMBL1815662 0.81 PNMT (0.55) AKR1B1FABP4ALDH1A1FEN1
SCHEMBL2866815 0.81 ALDH1A1 (0.47) AKR1B1CXCL8TTRPTGS2AKR1B10
SCHEMBL29933245 0.79 CXCL8 (0.65) AKR1B1CXCL8TTRPTGS2AKR1B10
SCHEMBL194831 0.79 CXCL8 (0.65) AKR1B1CXCL8TTRPTGS2AKR1B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-09-15 US disclosed
EP-2358682-A2 ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2011-08-24 EP disclosed
WO-2010055164-A2 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION MAVS, IRF3, EIF2AK2 AKR1B1 1119/4885DUSP3 157/4885PTPN5 1969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.